MSLN-BiTE

N/A

Report date: 2026/03/19 16:57:22

Base Information

Drug NameMSLN-BiTE

Drug Alias Nameanti-mesothelin/CD3 bispecific T-cell engager (Amgen)Anti-CD3/anti-mesothelin bispecific T-cell engager (Amgen)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionMesothelin modulatorsT cell surface glycoprotein CD3 inhibitors

TargetsT cell surface glycoprotein CD3Mesothelin

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesGermany

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAmgen Inc

China Registration ClassN/A

Develop Information

Active CompaniesAmgen Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A